URGN Stockholder Alert: Robbins LLP Informs Investors of the UroGen Pharma Ltd. Class Action Lawsuit
Provided By PR Newswire
Last update: May 30, 2025
SAN DIEGO, May 29, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025. UroGen engages in the development and commercialization of solutions for specialty cancers. The Company's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer.
Read more at prnewswire.com4.24
+0.27 (+6.8%)
Find more stocks in the Stock Screener
URGN Latest News and Analysis
17 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
17 days ago - ChartmillTop stock movements in today's session.Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
17 days ago - ChartmillThe market is filled with gapping stocks in Friday's session.The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
